CanSino Publishes Positive Data from COVID-19 Vaccine Trial in The Lancet
publication date: May 22, 2020
Tianjin CanSinoBIO published positive results from a China Phase I trial of its COVID-19 vaccine in the prestigious British journal, The Lancet. In the study, the Ad5 vectored COVID-19 vaccine was immunogenic at 28 days post-vaccination with only mild or moderate side effects. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and specific T-cell responses were noted from day 14 post-vaccination. The vaccine, which was based on CanSino's approved Ebola vaccine, has already started a Phase II trial. More details....
Stock Symbol: (HK: 6185)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.